Compare Covidh Technolog with Similar Stocks
Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Flat results in Dec 25
Risky - Negative EBITDA
Underperformed the market in the last 1 year
Stock DNA
Miscellaneous
INR 34 Cr (Micro Cap)
277.00
32
0.00%
-1.61
-12.00%
-33.18
Total Returns (Price + Dividend) 
Latest dividend: 0.5 per share ex-dividend date: Sep-20-2013
Risk Adjusted Returns v/s 
Returns Beta
News

Covidh Technologies Ltd Hits New 52-Week High of Rs.40.24
Covidh Technologies Ltd has surged to a fresh 52-week high of Rs.40.24, marking a significant milestone in its stock performance. This new peak reflects sustained momentum, with the stock demonstrating robust gains over the past month and outperforming its sector peers.
Read full news article Announcements 
Announcement under Regulation 30 (LODR)-Acquisition
23-Feb-2026 | Source : BSEPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations) as amended from time to time this is to inform that Covidh Technologies Limited (the Company) has executed a non-binding Letter of Intent (LOI) dated February 23 2026 with iSERA Biological Private Limited (iSERA) setting out the broad terms and conditions for the proposed acquisition of 100% equity shareholding of iSERA by the Company.
Announcement under Regulation 30 (LODR)-Acquisition
23-Feb-2026 | Source : BSEThis is with reference to the disclosure submitted by the Company on February 23 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations) regarding execution of a non-binding Letter of Intent (LOI) for the proposed acquisition. The Company hereby clarifies that the name of the target entity was inadvertently mentioned as iSERA Biological Private Limited in the aforesaid disclosure. The correct name of the target entity is iSERA Biological Limited.
Announcement under Regulation 30 (LODR)-Change in Registered Office Address
16-Feb-2026 | Source : BSEPursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that consequent to receipt of the Certificate of Registration of the Regional Directors Order for Change of State dated February 06 2026 issued by the Registrar of Companies Pune the Registered Office of the Company stands shifted from Hyderabad Telangana to Pune Maharashtra. Accordingly with immediate effect the Registered Office of the Company shall be deemed to be situated at the below-mentioned address and all official correspondence and business operations of the Company shall henceforth be carried out from this new address: Office No. 4 Kumar Prestige Point 238 Shukrawar Peth Pune City Maharashtra India - 411002.
Corporate Actions 
No Upcoming Board Meetings
Covidh Technologies Ltd has declared 5% dividend, ex-date: 20 Sep 13
No Splits history available
No Bonus history available
Covidh Technologies Ltd has announced 25:1 rights issue, ex-date: 24 Oct 25
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Ganapa Narsi Reddy (3.57%)
Dhairyasheel Vasantrao Yadav (13.26%)
91.1%
Quarterly Results Snapshot (Standalone) - Dec'25 - YoY
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 50.00% vs 33.33% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs -100.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -222.22% vs 70.97% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
YoY Growth in year ended Mar 2025 is 220.00% vs 0.00% in Mar 2024








